Cutera, Inc. (NASDAQ:CUTR) Director David B. Apfelberg sold 1,000 shares of the company’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $47.40, for a total transaction of $47,400.00. Following the transaction, the director now directly owns 8,259 shares of the company’s stock, valued at $391,476.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Cutera, Inc. (CUTR) traded down $0.55 during mid-day trading on Friday, reaching $45.90. 161,600 shares of the company were exchanged, compared to its average volume of 164,664. Cutera, Inc. has a 12 month low of $16.65 and a 12 month high of $48.95. The company has a market capitalization of $643.56, a P/E ratio of 59.55, a P/E/G ratio of 2.01 and a beta of 0.53.
Cutera (NASDAQ:CUTR) last released its quarterly earnings results on Tuesday, November 7th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.34. Cutera had a net margin of 7.99% and a return on equity of 18.73%. The company had revenue of $38.17 million during the quarter, compared to the consensus estimate of $34.82 million. During the same period in the prior year, the firm earned $0.12 earnings per share. Cutera’s revenue was up 26.1% on a year-over-year basis. equities research analysts anticipate that Cutera, Inc. will post 0.55 EPS for the current year.
Several brokerages have recently commented on CUTR. BidaskClub raised shares of Cutera from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. Zacks Investment Research downgraded shares of Cutera from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Roth Capital upped their price objective on shares of Cutera from $41.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, September 12th. Finally, Maxim Group downgraded shares of Cutera from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Cutera has an average rating of “Buy” and an average price target of $37.33.
TRADEMARK VIOLATION WARNING: “Cutera, Inc. (CUTR) Director Sells $47,400.00 in Stock” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/22/cutera-inc-cutr-director-sells-47400-00-in-stock.html.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.